Substance / Medication

Brexucabtagene autoleucel

Overview

Active Ingredient
brexucabtagene autoleucel
RxNorm CUI
2387277

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Long non-coding RNA as a novel biomarker and therapeutic target in aggressive B-cell non-Hodgkin lymphoma: A systematic review.
Khanmohammadi Shaghayegh, Fallahtafti Parisa · J Cell Mol Med · 2023
PMID: 37246627Meta-AnalysisFull text (PMC)
Unveiling the Prognostic Significance of BCL6+/CD10+ Mantle Cell Lymphoma: Meta-Analysis of Individual Patients and Systematic Review.
Castillo Dani Ran, Park Daniel, Jeon Won Jin et al. · Int J Mol Sci · 2023
PMID: 37373354Meta-AnalysisFull text (PMC)
Assessing the diagnosis of "primary cutaneous mantle cell lymphoma": A systematic review and population-based analysis.
Goyal Amrita, O'Leary Daniel, Foreman Ruth K et al. · J Am Acad Dermatol · 2022
PMID: 34343606Meta-Analysis
Efficacy and safety of ibrutinib in mantle cell lymphoma: A systematic review and meta-analysis.
Roufarshbaf Mohammad, Javeri Mohsen, Akbari Vajihe et al. · Daru · 2022
PMID: 36057010Meta-AnalysisFull text (PMC)
Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: A systematic literature review.
Monga Neerav, Tam Constantine, Garside Jamie et al. · Crit Rev Oncol Hematol · 2021
PMID: 33383209Meta-Analysis
ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed/refractory chronic lymphocytic leukemia.
Davids Matthew S, Kenderian Saad S, Flinn Ian et al. · Blood · 2025
PMID: 40209059Trial
Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy.
Jain Preetesh, Nastoupil Loretta, Westin Jason et al. · Br J Haematol · 2021
PMID: 33152104Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Brexucabtagene autoleucel (substance)
SNOMED CT
895363000
UMLS CUI
C5398046
RxNorm CUI
2387277

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.